John J Lima1, Mario Castro2, Tonya S King3, Jason E Lang4, Victor E Ortega5, Stephen P Peters5, Loren C Denlinger6, Elliot Israel7, Christine A Sorkness7, Michael E Wechsler8, Sally E Wenzel9, Lewis J Smith10. 1. Nemours Children's Health System, Jacksonville, Florida. Electronic address: jlima@nemours.org. 2. Washington University School of Medicine, St Louis, Missouri. 3. Penn State University, Hershey, Pennsylvania. 4. Duke University School of Medicine, Durham, North Carolina. 5. Wake Forest School of Medicine, Winston-Salem, North Carolina. 6. University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. 7. Brigham & Women's Hospital, Boston, Massachusetts. 8. National Jewish Health, Denver, Colorado. 9. University of Pittsburgh, Pittsburgh, Pennsylvania. 10. Northwestern University, Chicago, Illinois.
Abstract
BACKGROUND: Use of vitamin D3 serum concentrations as a biomarker of vitamin D status is questionable because of variation in vitamin D binding protein. OBJECTIVE: To determine associations between free vitamin D3 concentrations and rates of treatment failure and exacerbations in patients with asthma participating in the Vitamin D Add-on Therapy Enhances Corticosteroid Responsiveness in Asthma (VIDA) trial. METHODS:Free concentrations were directly measured by enzyme-linked immunosorbent assay and stratified into low, medium, and high groups: less than 5pg/mL (n = 65), 5 to 9pg/mL (n = 84), and greater than 9pg/mL (n = 48) after 12 weeks of supplementation with oral vitamin D3 and associated with outcomes. RESULTS: Outcomes did not associate with free concentrations: overall treatment failure rates were 0.60 (95% confidence interval [CI] 0.46-0.78), 0.53 (95%CI 0.40- 0.70), and 0.69 (95%CI 0.54-0.90)/person-year (P = .51), respectively; overall exacerbation rates were 0.28 (95%CI 0.17-0.48), 0.15 (95%CI 0.08-0.30) and 0.42 (95%CI 0.27-0.66)/person-year (P = .22). Mean (standard deviation) baseline free concentrations were lower in non-Hispanic blacks and Hispanics compared with non-Hispanic whites: 4.10 (1.33) and 4.38 (1.11) pg/mL vs 5.16 (1.65) pg/ml, (P < .001 and P = 0.038), respectively. Mean (standard deviation) baseline free concentrations differed between females and males: 4.57 (1.58) and 5.08 (1.41) (P = .026); and between non-overweight (body mass index [BMI] < 25) and overweight (BMI > 25): 5.45 (1.86) vs 4.54 (1.39) (P < .001). The free fraction differed by race and sex but not by BMI. CONCLUSION: The use of free concentrations was inferior to total concentrations as a biomarker of efficacy of vitamin D3 supplementation in VIDA trial participants. Future studies of vitamin D status in patients with asthma should measure both free and total concentrations to better understand which marker of vitamin D function is most informative.
RCT Entities:
BACKGROUND: Use of vitamin D3 serum concentrations as a biomarker of vitamin D status is questionable because of variation in vitamin D binding protein. OBJECTIVE: To determine associations between free vitamin D3 concentrations and rates of treatment failure and exacerbations in patients with asthma participating in the Vitamin D Add-on Therapy Enhances Corticosteroid Responsiveness in Asthma (VIDA) trial. METHODS: Free concentrations were directly measured by enzyme-linked immunosorbent assay and stratified into low, medium, and high groups: less than 5pg/mL (n = 65), 5 to 9pg/mL (n = 84), and greater than 9pg/mL (n = 48) after 12 weeks of supplementation with oral vitamin D3 and associated with outcomes. RESULTS: Outcomes did not associate with free concentrations: overall treatment failure rates were 0.60 (95% confidence interval [CI] 0.46-0.78), 0.53 (95%CI 0.40- 0.70), and 0.69 (95%CI 0.54-0.90)/person-year (P = .51), respectively; overall exacerbation rates were 0.28 (95%CI 0.17-0.48), 0.15 (95%CI 0.08-0.30) and 0.42 (95%CI 0.27-0.66)/person-year (P = .22). Mean (standard deviation) baseline free concentrations were lower in non-Hispanic blacks and Hispanics compared with non-Hispanic whites: 4.10 (1.33) and 4.38 (1.11) pg/mL vs 5.16 (1.65) pg/ml, (P < .001 and P = 0.038), respectively. Mean (standard deviation) baseline free concentrations differed between females and males: 4.57 (1.58) and 5.08 (1.41) (P = .026); and between non-overweight (body mass index [BMI] < 25) and overweight (BMI > 25): 5.45 (1.86) vs 4.54 (1.39) (P < .001). The free fraction differed by race and sex but not by BMI. CONCLUSION: The use of free concentrations was inferior to total concentrations as a biomarker of efficacy of vitamin D3 supplementation in VIDA trial participants. Future studies of vitamin D status in patients with asthma should measure both free and total concentrations to better understand which marker of vitamin D function is most informative.
Authors: Adrian R Martineau; Christopher J Cates; Mitsuyoshi Urashima; Megan Jensen; Alex P Griffiths; Ulugbek Nurmatov; Aziz Sheikh; Chris J Griffiths Journal: Cochrane Database Syst Rev Date: 2016-09-05
Authors: Jiyoung Ahn; Kai Yu; Rachael Stolzenberg-Solomon; K Claire Simon; Marjorie L McCullough; Lisa Gallicchio; Eric J Jacobs; Alberto Ascherio; Kathy Helzlsouer; Kevin B Jacobs; Qizhai Li; Stephanie J Weinstein; Mark Purdue; Jarmo Virtamo; Ronald Horst; William Wheeler; Stephen Chanock; David J Hunter; Richard B Hayes; Peter Kraft; Demetrius Albanes Journal: Hum Mol Genet Date: 2010-04-23 Impact factor: 6.150
Authors: Anne C Looker; Christine M Pfeiffer; David A Lacher; Rosemary L Schleicher; Mary Frances Picciano; Elizabeth A Yetley Journal: Am J Clin Nutr Date: 2008-12 Impact factor: 7.045
Authors: Mario Castro; Tonya S King; Susan J Kunselman; Michael D Cabana; Loren Denlinger; Fernando Holguin; Shamsah D Kazani; Wendy C Moore; James Moy; Christine A Sorkness; Pedro Avila; Leonard B Bacharier; Eugene Bleecker; Homer A Boushey; James Chmiel; Anne M Fitzpatrick; Deborah Gentile; Mandeep Hundal; Elliot Israel; Monica Kraft; Jerry A Krishnan; Craig LaForce; Stephen C Lazarus; Robert Lemanske; Njira Lugogo; Richard J Martin; David T Mauger; Edward Naureckas; Stephen P Peters; Wanda Phipatanakul; Loretta G Que; Ajay Sheshadri; Lewis Smith; Julian Solway; Lisa Sullivan-Vedder; Kaharu Sumino; Michael E Wechsler; Sally Wenzel; Steven R White; E Rand Sutherland Journal: JAMA Date: 2014-05 Impact factor: 56.272
Authors: Ken Batai; Adam B Murphy; Ebony Shah; Maria Ruden; Jennifer Newsome; Sara Agate; Michael A Dixon; Hua Yun Chen; Leslie A Deane; Courtney M P Hollowell; Chiledum Ahaghotu; Rick A Kittles Journal: Hum Genet Date: 2014-08-02 Impact factor: 4.132
Authors: Kathleen Lee-Sarwar; Rachel S Kelly; Jessica Lasky-Su; Priyadarshini Kachroo; Robert S Zeiger; George T O'Connor; Megan T Sandel; Leonard B Bacharier; Avraham Beigelman; Nancy Laranjo; Diane R Gold; Scott T Weiss; Augusto A Litonjua Journal: J Allergy Clin Immunol Pract Date: 2018-08-24
Authors: Rene F Chun; Albert Shieh; Carter Gottlieb; Vahe Yacoubian; Jeffrey Wang; Martin Hewison; John S Adams Journal: Front Endocrinol (Lausanne) Date: 2019-10-24 Impact factor: 6.055